Nanjing Cavendish Bio-engineering Technology Co., Ltd.
As of 20 November 2026, for the company name Nanjing Cavendish Bio-engineering Technology Co., Ltd. as recorded, the CDE acceptance records name it as first applicant on 19 records, across 12 drug names; the chemical-drug catalogue lists 17 active records with this name as holder.
Check drug filings and source records for this company-name string.
Listed by the company name as recorded in the source, without merging affiliated entities.
Page reference
These counts cover loaded acceptance records only. First-applicant and co-applicant counts are not added together. CDE data as of 2026/11/20.
Drug filings
19 acceptance records as first applicant, grouped into 12 source drug names. Source data as of 2026/11/20.
Acceptance records are de-duplicated by acceptance number. Drug names are normalized only for width and whitespace; dosage forms and combinations remain separate. Application types are retained from the source. Expand a drug to inspect each record. Published drugs link to their drug pages; other names do not create new public drug pages.
Nimodipine Injection 1 records · Latest accepted 2024/12/28
Generic · 1
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| CYHS2404613 | Generic | 2024/12/28 | Nanjing Cavendish Bio-engineering Technology Co., Ltd.; Yuan Da Pharmaceuticals (Zhongguo) Co., Ltd. romanized | CDE ↗ |
Progesterone Injection 1 records · Latest accepted 2024/12/06
Generic · 1
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| CYHS2404227 | Generic | 2024/12/06 | Nanjing Cavendish Bio-engineering Technology Co., Ltd.; Jilin Ao Dong Pharma Group Yan Ji Co., Ltd. romanized | CDE ↗ |
Metoclopramide Hydrochloride Injection 1 records · Latest accepted 2023/11/21
Generic · 1
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| CYHS2303190 | Generic | 2023/11/21 | Nanjing Cavendish Bio-engineering Technology Co., Ltd.; Zhejiang CDMO Pharmaceutical Co., Ltd. | CDE ↗ |
Arginine and Ibuprofen Granules 3 records · Latest accepted 2023/05/06
Generic · 3
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| CYHS2301222 | Generic | 2023/05/06 | Nanjing Cavendish Bio-engineering Technology Co., Ltd.; Jiangsu Yunyang Group Pharmaceutical Co.,Ltd. | CDE ↗ |
| CYHS2301221 | Generic | 2023/05/06 | Nanjing Cavendish Bio-engineering Technology Co., Ltd.; Jiangsu Yunyang Group Pharmaceutical Co.,Ltd. | CDE ↗ |
| CYHS2301220 | Generic | 2023/05/06 | Nanjing Cavendish Bio-engineering Technology Co., Ltd.; Jiangsu Yunyang Group Pharmaceutical Co.,Ltd. | CDE ↗ |
Pentoxifylline Injection 1 records · Latest accepted 2023/04/04
Generic · 1
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| CYHS2300961 | Generic | 2023/04/04 | Nanjing Cavendish Bio-engineering Technology Co., Ltd.; Jiangsu Yue Xing Pharma Co., Ltd. romanized | CDE ↗ |
Acetaminophen Injection 2 records · Latest accepted 2023/02/22
Generic · 2
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| CYHS2300609 | Generic | 2023/02/22 | Nanjing Cavendish Bio-engineering Technology Co., Ltd.; Jiangsu Wu Zhong Pharmaceuticals Group Co., Ltd. Suzhou Pharmaceutical Factory romanized | CDE ↗ |
| CYHS2300608 | Generic | 2023/02/22 | Nanjing Cavendish Bio-engineering Technology Co., Ltd.; Jiangsu Wu Zhong Pharmaceuticals Group Co., Ltd. Suzhou Pharmaceutical Factory romanized | CDE ↗ |
Ambroxol Hydrochloride and Clenbuterol Hydrochloride Oral Solution 1 records · Latest accepted 2023/02/18
Generic · 1
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| CYHS2300568 | Generic | 2023/02/18 | Nanjing Cavendish Bio-engineering Technology Co., Ltd.; Jiangsu Yunyang Group Pharmaceutical Co.,Ltd. | CDE ↗ |
Ambroxol Hydrochloride Oral Solution 1 records · Latest accepted 2023/02/18
Generic · 1
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| CYHS2300569 | Generic | 2023/02/18 | Nanjing Cavendish Bio-engineering Technology Co., Ltd.; Jiangsu Yunyang Group Pharmaceutical Co.,Ltd. | CDE ↗ |
Morinidazole and Sodium Chloride Injection 1 records · Latest accepted 2023/02/11
Generic · 1
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| CYHS2300474 | Generic | 2023/02/11 | Nanjing Cavendish Bio-engineering Technology Co., Ltd.; Jiangsu Yue Xing Pharma Co., Ltd. romanized | CDE ↗ |
Rivaroxaban Tablets 4 records · Latest accepted 2022/10/14
Supplement · 1Generic · 3
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| CYHB2201884 | Supplement | 2022/10/14 | Nanjing Cavendish Bio-engineering Technology Co., Ltd.; Jiangsu Yunyang Group Pharmaceutical Co.,Ltd. | CDE ↗ |
| CYHS2101095 | Generic | 2021/04/23 | Nanjing Cavendish Bio-engineering Technology Co., Ltd.; Jiangsu Yunyang Group Pharmaceutical Co.,Ltd. | CDE ↗ |
| CYHS2101094 | Generic | 2021/04/23 | Nanjing Cavendish Bio-engineering Technology Co., Ltd.; Jiangsu Yunyang Group Pharmaceutical Co.,Ltd. | CDE ↗ |
| CYHS2100015 | Generic | 2021/01/08 | Nanjing Cavendish Bio-engineering Technology Co., Ltd.; Jiangsu Yunyang Group Pharmaceutical Co.,Ltd. | CDE ↗ |
Eplerenone Tablets 2 records · Latest accepted 2021/12/17
Generic · 2
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| CYHS2102151 | Generic | 2021/12/17 | Nanjing Cavendish Bio-engineering Technology Co., Ltd.; Jiangsu Yunyang Group Pharmaceutical Co.,Ltd. | CDE ↗ |
| CYHS2102150 | Generic | 2021/12/17 | Nanjing Cavendish Bio-engineering Technology Co., Ltd.; Jiangsu Yunyang Group Pharmaceutical Co.,Ltd. | CDE ↗ |
Abiraterone Acetate Tablets 1 records · Latest accepted 2021/09/23
Generic · 1
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| CYHS2101758 | Generic | 2021/09/23 | Nanjing Cavendish Bio-engineering Technology Co., Ltd.; Jiangsu Yunyang Group Pharmaceutical Co.,Ltd. | CDE ↗ |
Changes in the last 90 days
0 events from 2026/08/23 to 2026/11/20. CDE data as of 2026/11/20; NMPA data as of 2026/11/19.
Last 90 days, ordered by fact date. Marketing approvals, trial registrations, supplements, notices and review changes are labelled separately. Fact dates are approval dates, acceptance dates, trial first-publication dates, or the date an application stopped being listed as under review. Publication dates and dates added to this site are listed separately. Historical records with earlier dates are not current-period new events. Exit records cover currently inactive applications whose delisting date is known, not a full review history.
- No matching records were found in the currently loaded source data; coverage dates are listed below.
Under review
0 acceptance numbers with this company as first applicant are currently listed as under review by CDE. Source data as of 2026/11/20.
| Drug | Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|---|
| No matching records were found in the currently loaded source data; coverage dates are listed below. | |||||
Catalogue holder records
17 loaded active catalogue records whose holder name matches this source company name. Source data as of 2026/11/20. Manufacturer-only records are excluded.
| Drug | Marketing authorization holder | Manufacturer | NMPA approval no. | Approved | Catalogue category (source text) | View source |
|---|---|---|---|---|---|---|
| Nimodipine Injection | Nanjing Cavendish Bio-engineering Technology Co., Ltd. | Yuan Da Pharmaceuticals (Zhongguo) Co., Ltd. romanized | 国药准字H20265775 | 2026/09/02 | Generic approved under the new chemical-drug registration classification | CDE ↗ |
| 黄体酮注射液(II) · No verified English name | Nanjing Cavendish Bio-engineering Technology Co., Ltd. | Jilin Ao Dong Pharma Group Yan Ji Co., Ltd. romanized | 国药准字H20265497 | 2026/08/04 | Generic approved under the new chemical-drug registration classification | CDE ↗ |
| 左奥硝唑氯化钠注射液 · No verified English name | Nanjing Cavendish Bio-engineering Technology Co., Ltd. | Jiangsu Wu Zhong Pharmaceuticals Group Co., Ltd. Suzhou Pharmaceutical Factory romanized | 国药准字H20265164 | 2026/07/14 | Generic approved under the new chemical-drug registration classification | CDE ↗ |
| 左奥硝唑氯化钠注射液 · No verified English name | Nanjing Cavendish Bio-engineering Technology Co., Ltd. | Jiangsu Wu Zhong Pharmaceuticals Group Co., Ltd. Suzhou Pharmaceutical Factory romanized | 国药准字H20265163 | 2026/07/14 | Generic approved under the new chemical-drug registration classification | CDE ↗ |
| Metoclopramide Hydrochloride Injection | Nanjing Cavendish Bio-engineering Technology Co., Ltd. | Zhejiang CDMO Pharmaceutical Co., Ltd. | 国药准字H20254636 | 2025/06/24 | Generic approved under the new chemical-drug registration classification | CDE ↗ |
| Morinidazole and Sodium Chloride Injection | Nanjing Cavendish Bio-engineering Technology Co., Ltd. | Jiangsu Yue Xing Pharma Co., Ltd. romanized | 国药准字H20249624 | 2024/12/01 | Generic approved under the new chemical-drug registration classification | CDE ↗ |
| Arginine and Ibuprofen Granules | Nanjing Cavendish Bio-engineering Technology Co., Ltd. | Jiangsu Yunyang Group Pharmaceutical Co.,Ltd. | 国药准字H20249088 | 2024/10/16 | Generic approved under the new chemical-drug registration classification | CDE ↗ |
| Pentoxifylline Injection | Nanjing Cavendish Bio-engineering Technology Co., Ltd. | Jiangsu Yue Xing Pharma Co., Ltd. romanized | 国药准字H20249098 | 2024/10/16 | Generic approved under the new chemical-drug registration classification | CDE ↗ |
| Arginine and Ibuprofen Granules | Nanjing Cavendish Bio-engineering Technology Co., Ltd. | Jiangsu Yunyang Group Pharmaceutical Co.,Ltd. | 国药准字H20249086 | 2024/10/16 | Generic approved under the new chemical-drug registration classification | CDE ↗ |
| Arginine and Ibuprofen Granules | Nanjing Cavendish Bio-engineering Technology Co., Ltd. | Jiangsu Yunyang Group Pharmaceutical Co.,Ltd. | 国药准字H20249087 | 2024/10/16 | Generic approved under the new chemical-drug registration classification | CDE ↗ |
| Eplerenone Tablets | Nanjing Cavendish Bio-engineering Technology Co., Ltd. | Jiangsu Yunyang Group Pharmaceutical Co.,Ltd. | 国药准字H20233980 | 2023/08/01 | Generic approved under the new chemical-drug registration classification | CDE ↗ |
| Eplerenone Tablets | Nanjing Cavendish Bio-engineering Technology Co., Ltd. | Jiangsu Yunyang Group Pharmaceutical Co.,Ltd. | 国药准字H20233974 | 2023/08/01 | Generic approved under the new chemical-drug registration classification | CDE ↗ |
| Abiraterone Acetate Tablets | Nanjing Cavendish Bio-engineering Technology Co., Ltd. | Jiangsu Yunyang Group Pharmaceutical Co.,Ltd. | 国药准字H20233177 | 2023/02/14 | Generic approved under the new chemical-drug registration classification | CDE ↗ |
| Rivaroxaban Tablets | Nanjing Cavendish Bio-engineering Technology Co., Ltd. | Jiangsu Yunyang Group Pharmaceutical Co.,Ltd. | 国药准字H20223583 | 2022/08/10 | Generic approved under the new chemical-drug registration classification | CDE ↗ |
| Rivaroxaban Tablets | Nanjing Cavendish Bio-engineering Technology Co., Ltd. | Jiangsu Yunyang Group Pharmaceutical Co.,Ltd. | 国药准字H20223582 | 2022/08/10 | Generic approved under the new chemical-drug registration classification | CDE ↗ |
| Rivaroxaban Tablets | Nanjing Cavendish Bio-engineering Technology Co., Ltd. | Jiangsu Yunyang Group Pharmaceutical Co.,Ltd. | 国药准字H20223244 | 2022/04/19 | Generic approved under the new chemical-drug registration classification | CDE ↗ |
| Apixaban Tablets | Nanjing Cavendish Bio-engineering Technology Co., Ltd. | Jiangsu Yunyang Group Pharmaceutical Co.,Ltd. | 国药准字H20213468 | 2021/06/08 | Generic approved under the new chemical-drug registration classification | CDE ↗ |
Only active catalogue records matching the source holder name are listed. A manufacturer role does not count as a holder record. The catalogue covers only part of the chemical-drug market; source categories do not establish complete market coverage or qualifications.
API registrations
0 loaded active API registrations whose first registered company matches this source company name. Source data as of 2026/11/20.
| Name | Company / applicant | Registration number | Status | Source update date | View source |
|---|---|---|---|---|---|
| No matching records were found in the currently loaded source data; coverage dates are listed below. | |||||
Only loaded active API registrations not listed as cancelled are shown. A/I are source registration statuses. Records are listed by registration number and do not establish capacity or supply. The register does not identify the associated formulation.
Co-applicant records
0 acceptance records name this company after the first applicant. They are listed separately and are not included in first-applicant drug or filing counts. Source data as of 2026/11/20.
| Drug | Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|---|
| No matching records were found in the currently loaded source data; coverage dates are listed below. | |||||
How current is each source?
- CDE acceptances and review
- Last successful update: 2026/11/20
- Chemical-drug catalogue
- Last successful update: 2026/11/20
- API registrations
- Last successful update: 2026/11/20
- NMPA drug delivery notices
- Last successful update: 2026/11/19
Loaded notices dated 2026-11-05 to 2026-11-19; 0 notices not yet loaded. Covers loaded notices only, not a complete historical approval database.
Listed by the company name as recorded in the source, without merging affiliated entities.
This page summarizes loaded records only. Parent companies, subsidiaries, former names and aliases are not merged. Counts from different sources must not be added together. No loaded record does not establish the absence of a filing or registration. Check original records where coverage is incomplete, an update has failed, or a source lies outside the loaded scope.
Fact dates are approval dates, acceptance dates, trial first-publication dates, or the date an application stopped being listed as under review. Publication dates and dates added to this site are listed separately. Historical records with earlier dates are not current-period new events. Exit records cover currently inactive applications whose delisting date is known, not a full review history.
Drugs with a verified official English name use that name only. Other drug names retain the Chinese source name marked No verified English name; names with a Chinese public page link to that page. Company labels use verified official names, Latin source names, then fixed-rule transliterations marked romanized; Chinese company names are not displayed. Marked unverified drug names and original statutory reference numbers may appear in Chinese.
Legal reference identifiers are retained verbatim. Company labels use official English entries where available, or a visibly marked fixed romanization. Unverified drug names retain the Chinese source name with a No verified English name marker. Other Chinese free text is not displayed; use the source links or source-name columns in CSV exports.